<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39335029</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-6382</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>Antibiotics (Basel, Switzerland)</Title><ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Consumption Trends of Antifungal and Antiprotozoal Agents for Human Systemic Use in Kazakhstan from 2017 to 2023.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">857</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics13090857</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">While multiple studies have investigated antibiotic consumption rates, there are few studies on the consumption of systemic antifungals and antiprotozoals. This study aims to fill this gap by providing a comprehensive analysis of nationwide consumption trends in Kazakhstan over a seven-year period (2017-2023).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Defined daily doses per 1000 inhabitants per day were calculated for systemic antifungals (J02 code of the Anatomical Therapeutic Chemical Classification System (ATC)) and antiprotozoals (P01 code of the ATC). Time series analyses were applied to examine historical trends, evaluate the impact of the COVID-19 pandemic, and make future projections until 2030.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The total consumption increased over the study period, with an average annual percent change of 1.11% for antifungals and 5.48% for antiprotozoals. Fluconazole was the most consumed antifungal agent, whereas metronidazole was the most consumed antiprotozoal agent. The COVID-19 pandemic had a positive but insignificant effect on the consumption of antifungals and a negative and also insignificant effect on the consumption of antiprotozoals. Forecast modeling indicates that the future trends in antifungal and antiprotozoal consumption until 2030 will largely remain stable, with the exception of antiprotozoal consumption in the hospital sector, which is projected to decline.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings offer valuable insights into the development and implementation of targeted antimicrobial stewardship programs in Kazakhstan.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Semenova</LastName><ForeName>Yuliya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-1324-7806</Identifier><AffiliationInfo><Affiliation>School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kussainova</LastName><ForeName>Assiya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kassym</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Practice with a Course of Evidence-Based Medicine, NJSC "Astana Medical University", Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aimurziyeva</LastName><ForeName>Ainur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Sciences and Humanities, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Semenov</LastName><ForeName>Daniil</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-2475-0976</Identifier><AffiliationInfo><Affiliation>Computer Science and Engineering Program, Astana IT University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><Identifier Source="ORCID">0009-0002-0857-9857</Identifier><AffiliationInfo><Affiliation>Graduate School of Public Policy, Nazarbayev University, Astana 010000, Kazakhstan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>211123CRP160</GrantID><Agency>Nazarbayev University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibiotics (Basel)</MedlineTA><NlmUniqueID>101637404</NlmUniqueID><ISSNLinking>2079-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kazakhstan</Keyword><Keyword MajorTopicYN="N">antifungal agents</Keyword><Keyword MajorTopicYN="N">antimicrobial stewardship</Keyword><Keyword MajorTopicYN="N">antiprotozoal agents</Keyword><Keyword MajorTopicYN="N">consumption</Keyword><Keyword MajorTopicYN="N">time series</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39335029</ArticleId><ArticleId IdType="pmc">PMC11440096</ArticleId><ArticleId IdType="doi">10.3390/antibiotics13090857</ArticleId><ArticleId IdType="pii">antibiotics13090857</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fang W., Wu J., Cheng M., Zhu X., Du M., Chen C., Liao W., Zhi K., Pan W. Diagnosis of invasive fungal infections: Challenges and recent developments. J. Biomed. Sci. 2023;30:42. doi: 10.1186/s12929-023-00926-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-023-00926-2</ArticleId><ArticleId IdType="pmc">PMC10278348</ArticleId><ArticleId IdType="pubmed">37337179</ArticleId></ArticleIdList></Reference><Reference><Citation>Kainz K., Bauer M.A., Madeo F., Carmona-Gutierrez D. Fungal infections in humans: The silent crisis. Microb. Cell. 2020;7:143–145. doi: 10.15698/mic2020.06.718.</Citation><ArticleIdList><ArticleId IdType="doi">10.15698/mic2020.06.718</ArticleId><ArticleId IdType="pmc">PMC7278517</ArticleId><ArticleId IdType="pubmed">32548176</ArticleId></ArticleIdList></Reference><Reference><Citation>Scariot D.B., Staneviciute A., Zhu J., Li X., Scott E.A., Engman D.M. Leishmaniasis and Chagas disease: Is there hope in nanotechnology to fight neglected tropical diseases? Front. Cell. Infect. Microbiol. 2022;12:1000972. doi: 10.3389/fcimb.2022.1000972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.1000972</ArticleId><ArticleId IdType="pmc">PMC9523166</ArticleId><ArticleId IdType="pubmed">36189341</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Awadhi M., Ahmad S., Iqbal J. Current Status and the Epidemiology of Malaria in the Middle East Region and Beyond. Microorganisms. 2021;9:338. doi: 10.3390/microorganisms9020338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9020338</ArticleId><ArticleId IdType="pmc">PMC7915327</ArticleId><ArticleId IdType="pubmed">33572053</ArticleId></ArticleIdList></Reference><Reference><Citation>Engels D., Zhou X.N. Neglected tropical diseases: An effective global response to local poverty-related disease priorities. Infect. Dis. Poverty. 2020;9:10. doi: 10.1186/s40249-020-0630-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-0630-9</ArticleId><ArticleId IdType="pmc">PMC6986060</ArticleId><ArticleId IdType="pubmed">31987053</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva A., Nobre H., Sampaio L., Jr., Nascimento B.D., da Silva C., de Andrade Neto J.B., Manresa Á., Pinazo A., Cavalcanti B., de Moraes M.O., et al. Antifungal and antiprotozoal green amino acid-based rhamnolipids: Mode of action, antibiofilm efficiency and selective activity against resistant Candida spp. strains and Acanthamoeba castellanii. Colloids Surf. B Biointerfaces. 2020;193:111148. doi: 10.1016/j.colsurfb.2020.111148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.colsurfb.2020.111148</ArticleId><ArticleId IdType="pubmed">32512371</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Bond S.E., Lee-Milner J., Conway B.R., Lattyak W.J., Aldeyab M.A. Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: Intervention time series analysis. JAC Antimicrob. Resist. 2024;6:dlae013. doi: 10.1093/jacamr/dlae013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlae013</ArticleId><ArticleId IdType="pmc">PMC10848649</ArticleId><ArticleId IdType="pubmed">38328263</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Lim L., Salpynov Z., Gaipov A., Jakovljevic M. Historical evolution of healthcare systems of post-soviet Russia, Belarus, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Uzbekistan, Armenia, and Azerbaijan: A scoping review. Heliyon. 2024;10:e29550. doi: 10.1016/j.heliyon.2024.e29550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2024.e29550</ArticleId><ArticleId IdType="pmc">PMC11036062</ArticleId><ArticleId IdType="pubmed">38655295</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutical Review of Kazakhstan  Roadmap for Containing Antibiotic Resistance Was Adopted in Kazakhstan.  [(accessed on 21 July 2023)].  Available online:  https://pharm.reviews/ru/novosti/novosti-kazakhstana/item/4512-v-rk-prinyata-dorozhnaya-karta-po-sderzhivaniyu-rezistentnosti-k-antibiotikam.</Citation></Reference><Reference><Citation>Balapasheva A.A., Smagulova G.A., Mussina A.Z., Ziganshina L.E., Nurgaliyeva Z.Z. Pharmacoepidemiological Analysis of Antibacterial Agents Used in a Provisional Hospital in Aktobe, Kazakhstan, in the Context of COVID-19: A Comparison with the Pre-Pandemic Period. Antibiotics. 2023;12:1596. doi: 10.3390/antibiotics12111596.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12111596</ArticleId><ArticleId IdType="pmc">PMC10668668</ArticleId><ArticleId IdType="pubmed">37998798</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Kassym L., Kussainova A., Aimurziyeva A., Makalkina L., Avdeyev A., Yessmagambetova A., Smagul M., Aubakirova B., Akhmetova Z., et al. Knowledge, Attitudes, and Practices towards Antibiotics and Antimicrobial Resistance, and Antibiotics Consumption in the Population of Kazakhstan. Antibiotics. 2024;13:718. doi: 10.3390/antibiotics13080718.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics13080718</ArticleId><ArticleId IdType="pmc">PMC11350668</ArticleId><ArticleId IdType="pubmed">39200018</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Pivina L., Khismetova Z., Auyezova A., Nurbakyt A., Kauysheva A., Ospanova D., Kuziyeva G., Kushkarova A., Ivankov A., et al. Anticipating the Need for Healthcare Resources Following the Escalation of the COVID-19 Outbreak in the Republic of Kazakhstan. J. Prev. Med. Public Health. 2020;53:387–396. doi: 10.3961/jpmph.20.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3961/jpmph.20.395</ArticleId><ArticleId IdType="pmc">PMC7733753</ArticleId><ArticleId IdType="pubmed">33296578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur H., Krishnamoorthi S., Dhaliwal N., Biswal M., Singh S., Muthu V., Rudramurthy S.M., Agarwal R., Ghoshal S., Singh S., et al. Antifungal prescription practices and consumption in a tertiary care hospital of a developing country. Mycoses. 2022;65:935–945. doi: 10.1111/myc.13514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/myc.13514</ArticleId><ArticleId IdType="pubmed">35934811</ArticleId></ArticleIdList></Reference><Reference><Citation>Barraza M., Barnafi N., Ortiz G., Torres J.P., Coria P., Catalán P., Palma J., Morales J. Evaluation of the prescription, consumption and costs of antifungal drugs in a pediatric hospital in Chile. Rev. Chil. Infectol. Organo Of. Soc. Chil. Infectol. 2018;35:351–357. doi: 10.4067/s0716-10182018000400351.</Citation><ArticleIdList><ArticleId IdType="doi">10.4067/s0716-10182018000400351</ArticleId><ArticleId IdType="pubmed">30534920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahme D., Ayoub M., Shaito K., Saleh N., Assaf S., Lahoud N. First trend analysis of antifungals consumption in Lebanon using the World Health Organization collaborating center for drug statistics methodology. BMC Infect. Dis. 2022;22:882. doi: 10.1186/s12879-022-07883-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07883-5</ArticleId><ArticleId IdType="pmc">PMC9700908</ArticleId><ArticleId IdType="pubmed">36434539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamim H., Sangeda R.Z., Bundala M., Mkumbwa S., Bitegeko A., Sillo H.B., Fimbo A.M., Chambuso M., Mbugi E.V. Utilization Trends of Antiviral and Antifungal Agents for Human Systemic Use in Tanzania from 2010 to 2017 Using the World Health Organization Collaborating Centre for Drug Statistics Methodology. Front. Trop. Dis. 2021;2:723991. doi: 10.3389/fitd.2021.723991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fitd.2021.723991</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathadka S., Yan V.K.C., Neoh C.F., Al-Badriyeh D., Kong D.C.M., Slavin M.A., Cowling B.J., Hung I.F.N., Wong I.C.K., Chan E.W. Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries. Drugs. 2022;82:1193–1205. doi: 10.1007/s40265-022-01751-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-022-01751-x</ArticleId><ArticleId IdType="pmc">PMC9402496</ArticleId><ArticleId IdType="pubmed">35960433</ArticleId></ArticleIdList></Reference><Reference><Citation>Gursoy S., Satıcı D., Kuzu B., Turkmenoglu B., Dilek E., Algul O. Exploring New 5-Nitroimidazole Derivatives as Potent Acetylcholinesterase and Butyrylcholinesterase Enzyme Inhibitors. Chem. Biodivers. 2024;20:e202400918. doi: 10.1002/cbdv.202400918. Advance online publication.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cbdv.202400918</ArticleId><ArticleId IdType="pubmed">38924646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nayiga S., Kayendeke M., Nabirye C., Willis L.D., Chandler C.I.R., Staedke S.G. Use of antibiotics to treat humans and animals in Uganda: A cross-sectional survey of households and farmers in rural, urban and peri-urban settings. JAC-Antimicrob. Resist. 2020;2:dlaa082. doi: 10.1093/jacamr/dlaa082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlaa082</ArticleId><ArticleId IdType="pmc">PMC8210029</ArticleId><ArticleId IdType="pubmed">34223037</ArticleId></ArticleIdList></Reference><Reference><Citation>Afari-Asiedu S., Hulscher M., Abdulai M.A., Boamah-Kaali E., Asante K.P., Wertheim H.F.L. Every medicine is medicine; exploring inappropriate antibiotic use at the community level in rural Ghana. BMC Public Health. 2020;20:1103. doi: 10.1186/s12889-020-09204-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-020-09204-4</ArticleId><ArticleId IdType="pmc">PMC7359511</ArticleId><ArticleId IdType="pubmed">32664902</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleem Z., Faller E.M., Godman B., Malik M.S.A., Iftikhar A., Iqbal S., Akbar A., Hashim M., Amin A., Javeed S., et al. Antibiotic consumption at community pharmacies: A multicenter repeated prevalence surveillance using WHO methodology. Med. Access Point Care. 2021;5:23992026211064714. doi: 10.1177/23992026211064714.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/23992026211064714</ArticleId><ArticleId IdType="pmc">PMC9413637</ArticleId><ArticleId IdType="pubmed">36204499</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzny C.A., Van Gerwen O.T., Legendre D. Secnidazole: A treatment for trichomoniasis in adolescents and adults. Expert Rev. Anti-Infect. Ther. 2022;20:1067–1076. doi: 10.1080/14787210.2022.2080656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2022.2080656</ArticleId><ArticleId IdType="pmc">PMC9844242</ArticleId><ArticleId IdType="pubmed">35642509</ArticleId></ArticleIdList></Reference><Reference><Citation>Baigenzhin A., Doskaliyev Z., Tuganbekova S., Zharikov S., Altynova S., Gaipov A. Organ Transplants in Kazakhstan. Exp. Clin. Transplant. Off. J. Middle East Soc. Organ Transplant. 2015;13:4–6. doi: 10.6002/ect.tdtd2015.L5.</Citation><ArticleIdList><ArticleId IdType="doi">10.6002/ect.tdtd2015.L5</ArticleId><ArticleId IdType="pubmed">26640900</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Beyembetova A., Shaisultanova S., Asanova A., Sailybayeva A., Altynova S., Pya Y. Evaluation of liver transplantation services in Kazakhstan from 2012 to 2023. Sci. Rep. 2024;14:9304. doi: 10.1038/s41598-024-60086-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-60086-7</ArticleId><ArticleId IdType="pmc">PMC11039733</ArticleId><ArticleId IdType="pubmed">38654041</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Shaisultanova S., Beyembetova A., Asanova A., Sailybayeva A., Novikova S., Myrzakhmetova G., Pya Y. Examining a 12-year experience within Kazakhstan’s national heart transplantation program. Sci. Rep. 2024;14:10291. doi: 10.1038/s41598-024-61131-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-61131-1</ArticleId><ArticleId IdType="pmc">PMC11069499</ArticleId><ArticleId IdType="pubmed">38704426</ArticleId></ArticleIdList></Reference><Reference><Citation>Avkan-Oğuz V., Irmak Ç., Dağdeviren K., Eren-Kutsoylu O., Nazlı A., Çelik M., Bayrak S. The Effect of the Pandemic on Antifungal Use: What Has Changed? Infect. Dis. Clin. Microbiol. 2022;4:156–162. doi: 10.36519/idcm.2022.144.</Citation><ArticleIdList><ArticleId IdType="doi">10.36519/idcm.2022.144</ArticleId><ArticleId IdType="pmc">PMC10985811</ArticleId><ArticleId IdType="pubmed">38633389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bienvenu A.L., Bestion A., Pradat P., Richard J.C., Argaud L., Guichon C., Roux S., Piriou V., Paillet C., Leboucher G., et al. Impact of COVID-19 pandemic on antifungal consumption: A multicenter retrospective analysis. Crit. Care. 2022;26:384. doi: 10.1186/s13054-022-04270-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04270-z</ArticleId><ArticleId IdType="pmc">PMC9745268</ArticleId><ArticleId IdType="pubmed">36514110</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutical Review of Kazakhstan  Pharmaceutical Market of the Republic of Kazakhstan: Current State and Development Prospects.  [(accessed on 31 July 2024)].  Available online:  https://pharm.reviews/ru/analitika/item/7111-farmatsevticheskij-rynok-rk-sostoyanie-i-perspektivy-razvitiya.</Citation></Reference><Reference><Citation>Kanj S.S., Haddad S.F., Meis J.F., Verweij P.E., Voss A., Rautemaa-Richardson R., Levy-Hara G., Chowdhary A., Ghafur A., Brüggemann R., et al. The battle against fungi: Lessons in antifungal stewardship from COVID 19 times. Int. J. Antimicrob. Agents. 2023;62:106846. doi: 10.1016/j.ijantimicag.2023.106846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2023.106846</ArticleId><ArticleId IdType="pmc">PMC10181945</ArticleId><ArticleId IdType="pubmed">37187336</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenova Y., Trenina V., Pivina L., Glushkova N., Zhunussov Y., Ospanov E., Bjorklund G. The lessons of COVID-19, SARS, and MERS: Implications for preventive strategies. Int. J. Healthc. Manag. 2023;15:314–324. doi: 10.1080/20479700.2022.2051126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20479700.2022.2051126</ArticleId></ArticleIdList></Reference><Reference><Citation>Vi-ORTIS  Market Research Company.  [(accessed on 29 July 2024)].  Available online:  https://base.viortis.kz/Account/LogOn?ReturnUrl=%2f.</Citation></Reference><Reference><Citation>Norwegian Institute of Public Health  ATC/DDD Index.  [(accessed on 29 July 2024)].  Available online:  https://atcddd.fhi.no/atc_ddd_index/?code=J&amp;showdescription=yes.</Citation></Reference><Reference><Citation>Agency for Strategic Planning and Reforms of the Republic of Kazakhstan  Bureau of National Statistics. Statistical Collections.  [(accessed on 29 July 2024)]; Available online:  https://stat.gov.kz/en/publication/collections/</Citation></Reference><Reference><Citation>Hollingworth S., Kairuz T. Measuring Medicine Use: Applying ATC/DDD Methodology to Real-World Data. Pharmacy. 2021;9:60. doi: 10.3390/pharmacy9010060.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmacy9010060</ArticleId><ArticleId IdType="pmc">PMC8006033</ArticleId><ArticleId IdType="pubmed">33802774</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  The ATC/DDD Methodology.  [(accessed on 31 July 2024)].  Available online:  https://www.who.int/tools/atc-ddd-toolkit/methodology.</Citation></Reference><Reference><Citation>World Health Organization . GLASS Manual on the Management of Antimicrobial Consumption Data. World Health Organization; Geneva, Switzerland: 2020.</Citation></Reference><Reference><Citation>Clegg L.X., Hankey B.F., Tiwari R., Feuer E.J., Edwards B.K. Estimating average annual per cent change in trend analysis. Stat. Med. 2009;28:3670–3682. doi: 10.1002/sim.3733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3733</ArticleId><ArticleId IdType="pmc">PMC2843083</ArticleId><ArticleId IdType="pubmed">19856324</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q., Hu J., Hu W., Li H., Lin G.Z. Interrupted time series analysis using the ARIMA model of the impact of COVID-19 on the incidence rate of notifiable communicable diseases in China. BMC Infect. Dis. 2023;23:375. doi: 10.1186/s12879-023-08229-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08229-5</ArticleId><ArticleId IdType="pmc">PMC10266306</ArticleId><ArticleId IdType="pubmed">37316780</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>